Showing 8,881 - 8,900 results of 32,032 for search '(( a step decrease ) OR ( 50 ((((we decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.06s Refine Results
  1. 8881
  2. 8882
  3. 8883
  4. 8884

    Actions to Include in a Farm Environment Plan by Annabel McAleer (15329209)

    Published 2024
    “…This interactive infographic is a compilation of actions to decrease the loss of contaminants from agricultural land. …”
  5. 8885

    Selective Inhibitors of Janus Kinase 3 Modify Responses to Lipopolysaccharides by Increasing the Interleukin-10-to-Tumor Necrosis Factor α Ratio by Julian Laux (13047767)

    Published 2023
    “…., tofacitinib, 0.2–0.4 μmol/kg bid) in clinical use, suggesting an efficient underlying mode of action. We hypothesized that their effectiveness is due to their ability to raise the ratio of IL-10 to TNFα. …”
  6. 8886

    Supplementary materials. by Yongki Welliam (21030005)

    Published 2025
    “…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”
  7. 8887
  8. 8888

    The Expression of Tubulin Cofactor A (TBCA) Is Regulated by a Noncoding Antisense <em>Tbca</em> RNA during Testis Maturation by Sofia Nolasco (144740)

    Published 2012
    “…In fact, as testis maturation progresses <em>Tbca</em>13 mRNA levels increase progressively, while <em>Tbca</em>16 mRNA levels decrease. This suggests a regulatory mechanism between the two genes and prompted us to investigate the presence of the two proteins. …”
  9. 8889
  10. 8890

    Summary of subgroup analysis results. by Yongki Welliam (21030005)

    Published 2025
    “…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”
  11. 8891

    PRISMA Flow Chart 2020. by Yongki Welliam (21030005)

    Published 2025
    “…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”
  12. 8892

    Included and excluded studies. by Yongki Welliam (21030005)

    Published 2025
    “…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”
  13. 8893

    Characteristics of included studies. by Yongki Welliam (21030005)

    Published 2025
    “…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”
  14. 8894

    Extraction data table. by Yongki Welliam (21030005)

    Published 2025
    “…Meta-analysis revealed that increasing OPN (SMD = 5.52, 95% CI = 1.59–9.44, p = 0.01) and KIM-1 (SMD = 1.45, 95% CI = 0.50–2.39, p = 0.0027), as well as decreasing Fetuin-A level (SMD = -1.31, 95% CI = -2.37 – -0.26, p = 0.01) were significant in CKD patients with ESRD. …”
  15. 8895
  16. 8896

    Transforming Small-Molecule Nanoaggregation into Functional Drug Delivery Platforms by JunHyuk Kim (21235657)

    Published 2025
    “…The IC<sub>50</sub> value of <b>Nano-CC1-Acl</b> further decreases to 0.20 ± 0.16 μM in the presence of cysteine, a biothiol. …”
  17. 8897

    Transforming Small-Molecule Nanoaggregation into Functional Drug Delivery Platforms by JunHyuk Kim (21235657)

    Published 2025
    “…The IC<sub>50</sub> value of <b>Nano-CC1-Acl</b> further decreases to 0.20 ± 0.16 μM in the presence of cysteine, a biothiol. …”
  18. 8898

    Cisd2 deficiency disrupts Ca<sup>2+</sup> homeostasis via a dysregulation of Serca2a activity and this then results in mitochondrial Ca<sup>2+</sup> overload and dysfunction in car... by Chi-Hsiao Yeh (7474556)

    Published 2019
    “…Scale bar, 5 μm. (N) Serca2a (Ca<sup>2+</sup>-ATPase) activity was measured as the decrease in the absorbance at 340 nm using heart tissue from the various genotypes. …”
  19. 8899

    Effects of Common Polymorphisms rs11614913 in <em>miR-196a2</em> and rs2910164 in <em>miR-146a</em> on Cancer Susceptibility: A Meta-Analysis by Wei Xu (28953)

    Published 2011
    “…Rs11614913 in <em>miR-196a2</em> and rs2910164 in <em>miR-146a</em> are shown to associate with increased/decreased cancer risk. …”
  20. 8900

    MiR-29a targets PTEN. by Guangyao Kong (185282)

    Published 2011
    “…Empty pcDNA3.0 plasmid (200 ng) was used as a negative control. (C) Luciferase reporter gene assay showed that the decreased luciferase activities of PTEN 3′UTR reporter (PTEN 3′UTR-1 or PTEN 3′UTR-2) in HepG2 cells mediated by miR-29a overexpression (200 ng) was rescued by a miR-29a inhibitor in a dose dependent manner (30, 50, and 100 nM). …”